Injection-free oral anemia treatment
Vafseo (vafseo.com) earns a Brand Analyzer score of 61 out of 100, placing it in the Developing tier among Healthcare brands. Among 2305 Healthcare brands analyzed, Vafseo ranks in the 17th percentile (category average 68, leader 95). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 62/100, Visual Identity 90/100, Messaging Clarity 100/100, Trust Foundation 53/100, AI Discoverability 66/100, Brand Authority 4/100.
Vafseo is a prescription oral medication indicated for the treatment of anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least three months. Administered as a once-daily pill, Vafseo offers an injection-free alternative to traditional anemia treatments for dialysis patients. The brand provides patient information and full prescribing information, including boxed warnings and a medication guide, through its website vafseo.com.
| Brand Name | Vafseo |
|---|---|
| Domain | vafseo.com |
| Industry | Healthcare |
| Main Competitors | Aranesp (Amgen) (82/100), Epogen (Amgen) (82/100), Mircera (Roche), Jesduvroq (GSK) (83/100), Auryxia (Akebia/Vifor) |
Moz Domain Authority 7/100 vs category average 29 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "See patient information for Vafseo, a new treatment option. See full Prescribing Information including BOXED WARNINGS, and Medication Guide." (Meta description: 19 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on Facebook, Instagram; no detected presence on X (Twitter), LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Vafseo scores 15/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Vafseo has a weak AI-visibility profile at 15/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (42/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 7/100.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Vafseo's main competitors include Aranesp (Amgen) (82/100), Epogen (Amgen) (82/100), Mircera (Roche), Jesduvroq (GSK), Auryxia (Akebia/Vifor). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Vafseo official site
Vafseo and Aranesp (Amgen) are competitors in Healthcare. Brand Analyzer scores Vafseo at 61/100 and Aranesp (Amgen) at 82/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Vafseo official site
Vafseo offers a single prescription product: a once-daily oral pill for the treatment of anemia caused by chronic kidney disease in adults on dialysis. The brand also provides patient information resources, a full prescribing information document including boxed warnings, and a medication guide through its website at vafseo.com.
Sources: Vafseo official site
Vafseo is a prescription oral medication indicated for the treatment of anemia in adults with chronic kidney disease (CKD) who are on dialysis. It is taken as a once-daily pill and is positioned as a convenient, injection-free alternative to other anemia treatments traditionally used in dialysis patients. Full prescribing information, including boxed warnings and a medication guide, is available for Vafseo.
Sources: Vafseo official site
Vafseo treats anemia caused by chronic kidney disease (CKD) in adult patients who are on dialysis. It is administered as a once-daily oral pill, providing an injection-free method of managing anemia in this patient population. By offering an oral treatment option, Vafseo aims to simplify the management of CKD-related anemia compared to injectable alternatives traditionally used in dialysis care.
Sources: Vafseo official site
Popular alternatives to Vafseo include Aranesp (Amgen) (82/100), Epogen (Amgen) (82/100), Mircera (Roche), Jesduvroq (GSK), Auryxia (Akebia/Vifor). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Vafseo official site
Vafseo has low AI-search visibility, scoring 15/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 14, recommendation 42). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Vafseo official site
Vafseo is intended for use by adults who have been on dialysis for at least three months and have anemia due to chronic kidney disease (CKD). It is a prescription medication, meaning it is prescribed and overseen by healthcare providers. The target population is specifically dialysis-dependent CKD patients experiencing anemia, distinguishing it from broader anemia treatments.
Sources: Vafseo official site
Vafseo is known for being a once-daily oral pill that treats anemia due to chronic kidney disease in adults on dialysis. It is specifically recognized as an injection-free alternative for anemia management in dialysis patients, offering a more convenient route of administration compared to injectable treatments that have historically been standard of care in this setting.
Sources: Vafseo official site
Vafseo scores 42/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Vafseo official site
Vafseo can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Vafseo official site
Ranked closest to Vafseo: Tredium Solutions, LLC (61/100), Travisoft (61/100), Vocca (61/100), Wellist (61/100).
A step up - brands to learn from: Zipari by mPulse (71/100), Zaina AI (71/100).
Category leader: Dassault Systèmes (95/100).